Neuroimaging correlates of HIV-associated BBB compromise

@article{Avison2004NeuroimagingCO,
  title={Neuroimaging correlates of HIV-associated BBB compromise},
  author={Malcolm Avison and Avindra Nath and Robin Greene-Avison and Frederick A. Schmitt and Richard N. Greenberg and Joseph R. Berger},
  journal={Journal of Neuroimmunology},
  year={2004},
  volume={157},
  pages={140-146}
}
The mechanisms underlying blood-brain barrier (BBB) compromise in human immunodeficiency virus (HIV) infection and the ways in which BBB compromise might impair neurocognitive function remain poorly understood. This study had two aims: (1) to examine the relationship between BBB breakdown, measured using contrast-enhanced magnetic resonance imaging (CE-MRI), plasma viral load, and neurological status; and (2) to examine the influence of highly active antiretroviral therapy (HAART) on the… Expand
Imaging correlates of the Blood Brain Barrier disruption in HIV associated neurocognitive disorder and therapeutic implications.
TLDR
This study indicates that HAND in the context of viral suppression is associated withBBB disruption and the DCE MR derived K-trans metric is a very sensitive parameter to identify the BBB disruption. Expand
Biomarkers of HIV-1 CNS infection and injury
TLDR
Two major avenues are now actively pursued: analysis of soluble molecular markers in CSF and, to a lesser degree, in blood, and neuroimaging markers using anatomic, metabolic, and functional measurements, which consider the rationale and prospects of these approaches. Expand
Combination of HIV-1 and Diabetes Enhances Blood Brain Barrier Injury via Effects on Brain Endothelium and Pericytes
TLDR
This study demonstrates for the first-time evidence of impaired BBB function in HIV-DM patients and shows potential mechanisms leading to it in brain endothelium and pericytes that may result in poorer cognitive performance compared to individuals without HIV and DM. Expand
HIV-1 neuroimmunity in the era of antiretroviral therapy
TLDR
Current therapeutic approaches are focused on adjunctive and brain-penetrating antiretroviral therapies that may attenuate virus-associated neuroinflammatory activities thereby decreasing the severity and frequency of HAND. Expand
Human brain imaging in HIV and neuroAIDS
TLDR
The purpose of this chapter is to highlight the significance of brain neuroimaging techniques and biomarkers in understanding the pathophysiology related to HIV infection and HAND. Expand
Blood-Brain Barrier Abnormalities Caused by HIV-1 gp120: Mechanistic and Therapeutic Implications
TLDR
HIV-envelope gp120 disrupts the blood-brain barrier; this occurs via lesions in brain microvessels, MMP activation and degradation of vascular basement membrane and vascular tight junctions; NMDAR-1 activation plays a role in this BBB injury; and antioxidant gene delivery as well as NMDar-1 antagonists may protect the BBB. Expand
Role of Oxidative Stress in HIV-1-Associated Neurocognitive Disorder and Protection by Gene Delivery of Antioxidant Enzymes
TLDR
The role of oxidative stress in animal models of HIV-1 Associated Neurocognitive Disorder (HAND) and in patients with HAND is reviewed to provide a better understanding of the pathogenesis of HIV -1 in the brain as well as offer new therapeutic avenues. Expand
CSF Penetration by Antiretroviral Drugs
TLDR
Although a substantial number of studies examined CSF concentrations of antiretroviral drugs, there is a need for adequate, well designed trials to provide more valid drug distribution profiles and for methodological issues to be addressed. Expand
The imaging of HIV-related brain disease
TLDR
Earlier treatment with HAART in at-risk or minimally symptomatic patients may prevent further decline in cognition and delay the course of HIV disease. Expand
Evolving paradigms in the pathogenesis of HIV-1-associated dementia.
TLDR
Mechanisms for neuronal injury and apoptosis, including the role of virus, viral and host proteins, oxidative stress and products of infected or uninfected activated microglia and astrocytes, are explored. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 54 REFERENCES
Metabolic characterization of AIDS dementia complex by spectroscopic imaging
TLDR
Reduced NAA seems to indicate progressive neuronal injury or loss due to productive HIV infection in the brain and its clinical picture ADC, and may serve as an early quantitative marker of central nervous system involvement in AIDS. Expand
Blood‐brain barrier abnormalities in acquired immunodeficiency syndrome: Immunohistochemical localization of serum proteins in postmortem brain
TLDR
Results indicate that a diffuse BBB leak is present in approximately 50% of all patients with AIDS at the time of autopsy and may be seen in the absence of any other brain pathology, including HIVE. Expand
Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex
TLDR
In early stages of HIV–CMC, frontal white matter showed evidence of glial proliferation and cell membrane injury, but no significant neuronal injury, while HIV–MCMD and HIV–dementia patients have different neurochemical abnormalities. Expand
Highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia
TLDR
1H MRS detects improvement of brain injury measured by cerebral metabolites, particularly the glial marker [MI], in patients with early HIV-CMC after HAART, in addition to systemic measures of HIV infection. Expand
Brain imaging in acquired immunodeficiency syndrome dementia complex.
TLDR
Functional neuroimaging, both PET and SPECT, can demonstrate abnormalities in the subcortical gray matter structures and the cerebral cortex in patients with ADC, and may be useful to follow progression of the dementia or response to therapy. Expand
Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia.
TLDR
FDG-PET scans provide quantitative measures of abnormal functional connectivity in HIV-seropositives-with or without AIDS or ADC, and appear to track the progression of CNS involvement in patients with subclinical neurologic or neuropsychologic dysfunction. Expand
Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV patients
TLDR
1H MRS imaging detects higher Cho in subcortical brain early in HIV disease, when individuals are clinically and neuropsychologically asymptomatic, whereas lower NAA is only found in sub cORTical brain in individuals with severe neuropsychological impairments. Expand
Patterns of cerebral atrophy in HIV–1–infected individuals
TLDR
Overall cerebral atrophy and prominent caudate region atrophy are important radiographie features of HIV dementia, and both the VBR and the BCR are significantly associated with dementia. Expand
Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV-induced lesions of the brain, correlations with HIV-associated disorders and modifications according to treatments.
TLDR
It is concluded that neuronal apoptosis is a late event and does not represent the main pathological substrate of HIVD, and the dementia more likely reflects a specific neuronal dysfunction resulting from the combined effects of several mechanisms, some of which may be reversible. Expand
Intrathecal IgG synthesis and albumin leakage are increased in subjects with HIV-1 neurologic disease.
TLDR
It is confirmed, using state-of-the-art albumin and IgG determinations, that intrathecal IgG synthesis is prevalent in all stages of HIV-1 disease. Expand
...
1
2
3
4
5
...